PetIQ (PETQ) Catches Eye: Stock Jumps 8.4%
- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
- PETQ
- ^GSPC
PetIQ, Inc. PETQ was a big mover last session, as the company saw its shares rise more than 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $22.35 –$29.84 in the past one-month time frame, witnessed a sharp increase on Friday.
The stock gained after the company announced the pricing of $125 million convertible senior notes related to the funding of Capstar acquisition.
The company has seen three negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
PetIQ currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
PetIQ, Inc. Price
PetIQ, Inc. price | PetIQ, Inc. Quote
A better-ranked stock in the Medical - Products industry is Apyx Medical Corporation APYX, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetIQ, Inc. (PETQ) : Free Stock Analysis Report
Bovie Medical Corporation (APYX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research